Official Website: Inherent Biosciences

Summary

Inherent Biosciences' official website describes a mission to replace trial-and-error medicine with epigenetic diagnostics, beginning in reproductive health. The site highlights SpermQT, marketed through its Path Fertility division, as an epigenetic sperm-function test intended to improve fertility diagnosis and treatment planning.

Useful Claims

• The company states its vision is to "revolutionize trial and error medicine to restore hope" by using biology inherent in cells to remove diagnostic guesswork.
• Initial focus areas listed include male infertility, sperm age, embryo quality, azoospermia, and reproductive cancers.
• The site explains epigenetics as the study of gene-expression changes rather than alterations to the genetic code itself.
• Inherent says it uses AI to identify observable epigenetic patterns in sperm correlated with fertility outcomes, with implications for other indications.
• Path Fertility, described as a division of Inherent Biosciences, markets SpermQT to raise the standard of care in reproductive health and provide more personalized treatment plans.
• SpermQT is positioned to address inequity in fertility testing and help couples achieve pregnancy faster through better diagnostic signal than count-and-motility alone.

Verbatim

"Our vision is to revolutionize trial and error medicine to restore hope" — Home page, heading

"We are on a mission to use what's inherent in our biology to remove the guesswork in diagnosing and treating complex diseases , starting in reproductive health." — Home page, mission statement

"Path Fertility, a division of Inherent Biosciences, markets SpermQT to address the inequity in fertility testing and provide couples with more personalized and effective treatment plans to achieve pregnancy faster." — Home page, "What We Do"

Reliability Notes

This is an official company source. It is useful for product positioning, epigenetic-mechanism framing, and go-to-market language, but clinical validation, sensitivity/specificity, reimbursement status, and generalization beyond fertility should be cross-checked with peer-reviewed studies, regulatory filings, and independent clinical reporting.

Related Pages

• Inherent Biosciences

See Also

• Nucleus Utah: Redefining male fertility · https://www.nucleusutah.org/newsroom/redefining-male-fertility-inside-inherent-biosciences-growth — third-party Utah ecosystem profile